The FDA approved ribociclib, a CDK4/6 inhibitor, providing an additional treatment option for patients with early breast cancer at high risk for recurrence.

Ribociclib succinate is under clinical development by Novartis and currently in Phase II for Triple-Negative Breast Cancer (TNBC).

A panelist discusses how the phase 2 ELECTRA trial studies elacestrant in combination with ribociclib as first-line therapy for ER+/HER2– advanced breast cancer in postmenopausal women.

Ribociclib plus endocrine therapy shows PFS benefit in luminal B/HER2E breast cancer subtypes compared to chemotherapy, especially with low immune-related gene expression. Ribociclib (Kisqali) and ...

What was the safety profile of ribociclib (Kisqali) in the phase 3 NATALEE trial (NCT03701334)? JHAVERI: Neutropenia is the most common toxicity. All-grade neutropenia [occurred in] 62% [of patients] ...

The most frequently used standard treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer patients consists of a CDK4/6 ...

A phase 1 trial of camizestrant with ribociclib appears safe and effective in patients with ER+/HER2- advanced breast cancer. Treatment with camizestrant plus ribociclib (Kisqali) induced a median ...

Camizestrant with Kisqali is effective and tolerable for ER-positive/HER2-negative advanced breast cancer, with a median PFS of 8.1 months for both doses. Objective ...

Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients ...

ribociclib, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. Results as of September 25, 2024 ...

Detailed price information for Olema Pharmaceuticals Inc (OLMA-Q) from The Globe and Mail including charting and trades.